ROVALPITUZUMAB TESIRINE: 31 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
31
Total FAERS Reports
5 (16.1%)
Deaths Reported
30
Hospitalizations
31
As Primary/Secondary Suspect
14
Life-Threatening
2
Disabilities
First Report: 20171107 · Latest Report: 20181108
What Are the Most Common ROVALPITUZUMAB TESIRINE Side Effects?
#1 Most Reported
Hyperammonaemic encephalopathy
8 reports (25.8%)
#2 Most Reported
Pleural effusion
4 reports (12.9%)
#3 Most Reported
Sepsis
3 reports (9.7%)
All ROVALPITUZUMAB TESIRINE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Hyperammonaemic encephalopathy | 8 | 25.8% | 0 | 8 |
Who Reports ROVALPITUZUMAB TESIRINE Side Effects? Age & Gender Data
Gender: 45.2% female, 54.8% male. Average age: 52.1 years. Most reports from: US. View detailed demographics →
Is ROVALPITUZUMAB TESIRINE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2017 | 3 | 1 | 3 |
| 2018 | 19 | 3 | 19 |
What Is ROVALPITUZUMAB TESIRINE Used For?
| Indication | Reports |
|---|---|
| Small cell lung cancer | 19 |
| Hepatocellular carcinoma | 6 |
Official FDA Label for ROVALPITUZUMAB TESIRINE
Official prescribing information from the FDA-approved drug label.